Minimal Side Effects with New Class of Breast Cancer Drugs
Recent history of CDK Inhibitors
Research has been conducted on HR+ breast cancer for quite some time, and recently, medicines were developed that target and alter the hormone receptors in cancerous cells. The first drug to be approved by the US Food and Drug Administration (FDA) was palbociclib in February of 2015, which was marketed to breast cancer patients as Ibrance. The drug ribociclib was approved a couple of years later in March of 2017, and was marketed to breast cancer patients under the name Kisqali.
